Iron Sucrose Injection Manufacturer from Thane

Iron Sucrose Injection

Rs 50 / Piece

Strength: 100 mg
Packaging size: 5 ml
Weight: 34,000-60,000 daltons
Osmolarity: 1150 and 1350 mOsmol/L
Composition: Ferric hydroxide

We are leading manufacturer and exporter of Iron Sucrose Injection and our product is made up of good quality.

Capitalizing on strong industrial experience, we offer well formulated range of Yashifer (Iron Sucrose Injection).

Our injection is brown in color and is an aqueous, complex of polynuclear Iron (III)-hydroxide in sucrose (Iron Sucrose) that can be used for intravenously.

It has a molecular weight of approximately 34,000-60,000 daltons and each ml includes 20 mg elemental Iron as Iron Sucrose is water for injection.

The dosage is available in 5 mL single dose ampoule (100 mg elemental Iron per 5 mL).

It has 30% sucrose w/v (300 mg/mL) with a pH of 10.5-11.1. Yashifer is free from harmful preservatives and is extremely safe for health.

It fulfills the required iron content in the body and increases RBC count.

Additionally, it has Osmolarity is not less than 1150 and 1350 mOsmol/L.

Composition:	Each 5 mL contains: ferric hydroxide in complex with sucrose, equivalent to elemental iron 100 mg, water for injection Ph. Eur. q. s. to 5 mL
Theraupeutic category:	Iron Supplement

Clinical pharmacology:
Pharmacodynamics:	Following intravenous administration, iron sucrose is dissociated by the reticuloendothelial system into iron and sucrose.
Pharmacokinetics:	Following intravenous doses of iron sucrose, the iron component exhibits first order kinetics with an elimination half-life of 5 hours, total clearance of 1.2L/h, non-steady state apparent volume of distribution of 10.0L and steady state apparent volume of distribution of 7.9 L. Since iron disappearance from serum depends on the need for iron in the iron stores and iron utilizing tissues of the body, serum clearance of iron is expected to the more rapid in Iron deficient patients treated with Iron sucrose as compared to healthy individuals. The effects of age and gender on the pharmacokinetics of Iron Sucrose have not been studied.
Distribution:	Following intravenous administration of Iron Sucrose, the iron component appears to distribute mainly in blood to some extent in extra vascular fluid. Significant amount of administered Iron is distributed in the liver, spleen and bone marrow.
Metabolism and elimination:	Following intravenous administration, Iron Sucrose dissociates into iron and sucrose by the reticuloendothelial system. The sucrose component is eliminated mainly by urinary excretion.
Indications and usage:	Hemodialysis dependant chronic kidney disease (HDD-CKD) patients receiving an erythropoietin Peritoneal dialysis dependant chronic kidney disease (PDD-CKD) patients receiving an erythropoietin Non-dialysis dependant chronic kidney disease (NDD-CKD) patients receiving or not an erythropoietin Other conditions where oral Iron therapy is considered inadequate and parenteral iron therapy is indicated